Hemostatic Abnormalities and Relationships to Metabolic and Hormonal Status in Polycystic Ovarian Syndrome

被引:21
作者
Burchall, Genia [1 ]
Linden, Matthew D. [1 ]
Teede, Helena [2 ]
Piva, Terrence J. [1 ]
机构
[1] RMIT Univ, Sch Med Sci, Bundoora, Vic 3083, Australia
[2] Monash Univ, Sch Publ Hlth & Prevent Med, Clayton, Vic 3800, Australia
关键词
ACTIVATABLE FIBRINOLYSIS INHIBITOR; CARDIOVASCULAR RISK-FACTOR; PLASMINOGEN-ACTIVATOR; INSULIN-RESISTANCE; YOUNG-WOMEN; ASYMMETRICAL DIMETHYLARGININE; ENDOTHELIAL DYSFUNCTION; POSTMENOPAUSAL WOMEN; PROTHROMBOTIC STATE; ANTIGEN LEVELS;
D O I
10.1016/j.tcm.2012.01.001
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Polycystic ovarian syndrome (PCOS), diagnosed based on hyperandrogenism, ovulatory dysfunction, and polycystic ovaries, is one of the most common disorders of reproductive-aged females. Etiology includes both genetic and environmental/lifestyle factors contributing to both insulin resistance and hyperandrogenism. Clinically, PCOS has reproductive, psychological, and metabolic features, the latter predisposing to cardiovascular disease (CVD). Hemostatic abnormalities have an association with and a demonstrated pathophysiological role in CVD in non-PCOS populations but have not been adequately explored in PCOS. This review focuses on the hemostatic system in PCOS, exploring also relationships to the metabolic and hormonal abnormalities of the syndrome, and aims to identify whether hemostatic abnormalities are present as potential contributors to increased cardiovascular risk. Ultimately, this area may reveal preventative and therapeutic opportunities, which could improve the cardiovascular health of women with PCOS. (Trends Cardiovasc Med 2011;21:6-14) Crown Copyright (C) 2011 Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:6 / 14
页数:9
相关论文
共 64 条
[1]
Alexander CJ, 2009, REV CARDIOVASC MED, V10, P83
[2]
Andiran N, 2005, J PEDIATR ENDOCR MET, V18, P1373
[3]
The plasminogen activator system in women with polycystic ovary syndrome [J].
Atiomo, WU ;
Bates, SA ;
Condon, JE ;
Shaw, S ;
West, JH ;
Prentice, AG .
FERTILITY AND STERILITY, 1998, 69 (02) :236-241
[4]
Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS) [J].
Atiomo, WU ;
Fox, R ;
Condon, JE ;
Shaw, S ;
Friend, JJ ;
Prentice, AG ;
Wilkin, TJ .
CLINICAL ENDOCRINOLOGY, 2000, 52 (04) :487-492
[5]
Immunohistochemical detection of plasminogen activator inhibitor-1 in polycystic ovaries [J].
Atiomo, WU ;
Hilton, D ;
Fox, DHR ;
Lee, D ;
Shaw, S ;
Friend, J ;
Wilkin, TJ ;
Prentice, AG .
GYNECOLOGICAL ENDOCRINOLOGY, 2000, 14 (03) :162-168
[6]
Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span [J].
Azziz, R ;
Marin, C ;
Hoq, L ;
Badamgarav, E ;
Song, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (08) :4650-4658
[7]
Azziz R, 2009, EPIDEMIOLOGY PATHOGE
[8]
Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome [J].
Berneis, Kaspar ;
Rizzo, Manfredi ;
Lazzaroni, Veronica ;
Fruzzetti, Franca ;
Carmina, Enrico .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (01) :186-189
[9]
Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease [J].
Boulman, N ;
Levy, Y ;
Leiba, R ;
Shachar, S ;
Linn, R ;
Zinder, O ;
Blumenfeld, Z .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2160-2165
[10]
Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome [J].
Carmassi, F ;
De Negri, F ;
Fioriti, R ;
De Giorgi, A ;
Giannarelli, C ;
Fruzzetti, F ;
Pedrinelli, R ;
Dell'Omo, G ;
Bersi, C .
THROMBOSIS RESEARCH, 2005, 116 (03) :207-214